Trial Profile

Multicenter Phase I/II Trial of Ruxolitinib in Combination With Decitabine in Patients With Accelerated Phase Myeloproliferative Neoplasm (MPN) or Post-MPN AML

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Decitabine (Primary) ; Ruxolitinib (Primary)
Indications Acute myeloid leukaemia; Essential thrombocythaemia; Myelodysplastic syndromes; Myelofibrosis; Myeloproliferative disorders; Polycythaemia vera
Focus Adverse reactions; Therapeutic Use

Most Recent Events

26 Feb 2019 Status changed from active, no longer recruiting to completed.
26 Feb 2019 Status changed from active, no longer recruiting to completed.
04 Dec 2018 Final results of the phase 2 combination of Ruxolitinib + Decitabine presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com